慢性阻塞性肺疾病患者的α-1抗胰蛋白酶替代治疗
Alpha-1 Antitrypsin Replacement in Patients With COPD.
作者信息
Wells Adam D, Woods Anna, Hilleman Daniel E, Malesker Mark A
出版信息
P T. 2019 Jul;44(7):412-415.
Abstract
Chronic obstructive pulmonary disease can be attributed to genetic conditions and predispositions, among other factors. Alpha-1 antitrypsin deficiency (AATD) is a significant risk factor for COPD development and progression, and aggressive screening for all patients with COPD or adult-onset asthma is encouraged.
摘要
慢性阻塞性肺疾病可归因于遗传状况和易感性等多种因素。α-1抗胰蛋白酶缺乏症（AATD）是慢性阻塞性肺疾病发生和进展的重要危险因素，因此鼓励对所有慢性阻塞性肺疾病患者或成年期发病的哮喘患者进行积极筛查。
相似文献
1
Alpha-1 Antitrypsin Replacement in Patients With COPD.慢性阻塞性肺疾病患者的α-1抗胰蛋白酶替代治疗
P T. 2019 Jul;44(7):412-415.
2
An Alpha-1 Antitrypsin Deficiency Screening Study in Patients with Chronic Obstructive Pulmonary Disease, Bronchiectasis, or Asthma in Turkey.土耳其慢性阻塞性肺疾病、支气管扩张或哮喘患者的α-1 抗胰蛋白酶缺乏症筛查研究。
Int J Chron Obstruct Pulmon Dis. 2023 Nov 28;18:2785-2794. doi: 10.2147/COPD.S425835. eCollection 2023.
3
Recurrence of emphysema post-lung transplantation in a patient with alpha 1 antitrypsin deficiency (AATD).α1抗胰蛋白酶缺乏症（AATD）患者肺移植后肺气肿复发
Respir Med Case Rep. 2020 Nov 26;31:101309. doi: 10.1016/j.rmcr.2020.101309. eCollection 2020.
4
Impact of a Computerized Clinical Decision Support System to Improve Chronic Obstructive Pulmonary Disease Diagnosis and Testing for Alpha-1 Antitrypsin Deficiency.计算机临床决策支持系统对改善慢性阻塞性肺疾病诊断和α-1 抗胰蛋白酶缺乏症检测的影响。
Ann Am Thorac Soc. 2023 Aug;20(8):1116-1123. doi: 10.1513/AnnalsATS.202211-954OC.
5
Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.α-1抗胰蛋白酶缺乏症慢性阻塞性肺疾病患者的主动病例筛查及静脉注射α-1抗胰蛋白酶治疗的指征：最新进展
Arch Bronconeumol. 2015 Apr;51(4):185-92. doi: 10.1016/j.arbres.2014.05.008. Epub 2014 Jul 12.
6
Advances in managing COPD related to α -antitrypsin deficiency: An under-recognized genetic disorder.α-抗胰蛋白酶缺乏症相关 COPD 的治疗进展：一种被低估的遗传性疾病。
Allergy. 2018 Nov;73(11):2110-2121. doi: 10.1111/all.13558. Epub 2018 Jul 26.
7
Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.α-1抗胰蛋白酶缺乏症所致肺部疾病的治疗：一项系统评价
Int J Chron Obstruct Pulmon Dis. 2017 May 2;12:1295-1308. doi: 10.2147/COPD.S130440. eCollection 2017.
8
One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States.美国慢性阻塞性肺疾病患者中α-1抗胰蛋白酶缺乏症的一年患病率、合并症及住院费用
J Health Econ Outcomes Res. 2017 Jul 21;5(1):65-74. doi: 10.36469/9799. eCollection 2017.
9
Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease Patients with Underlying Alpha-1 Antitrypsin Deficiency: A Systematic Review and Practical Recommendations.患有潜在α-1抗胰蛋白酶缺乏症的慢性阻塞性肺疾病患者的肺康复：系统评价与实用建议
Chronic Obstr Pulm Dis. 2024 Jan 25;11(1):121-132. doi: 10.15326/jcopdf.2023.0434.
10
Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease.α1-抗胰蛋白酶缺乏症和慢性阻塞性肺疾病中肺气肿的独特和共有系统性生物标志物。
EBioMedicine. 2022 Oct;84:104262. doi: 10.1016/j.ebiom.2022.104262. Epub 2022 Sep 22.
引用本文的文献
1
Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits.慢性阻塞性肺疾病的新兴疗法：将创新与可治疗特征相对应
Lung. 2025 Sep 3;203(1):92. doi: 10.1007/s00408-025-00844-0.
2
Clinical and Economic Outcomes in Patients With Alpha-1 Antitrypsin Deficiency in a US Medicare Advantage Population.美国医疗保险优势人群中α-1抗胰蛋白酶缺乏症患者的临床和经济结局
J Health Econ Outcomes Res. 2025 Feb 20;12(1):66-74. doi: 10.36469/001c.127446. eCollection 2025.
3
Evaluation of Salivary Biomarkers and Spirometry for Diagnosing COPD in Non-Smokers and Smokers of Polish Origin.唾液生物标志物和肺活量测定法在诊断波兰裔非吸烟者和吸烟者慢性阻塞性肺疾病中的应用评估
Biomedicines. 2024 May 29;12(6):1206. doi: 10.3390/biomedicines12061206.
4
Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer.导致 COPD 和肺癌合并症的机制。
Int J Mol Sci. 2023 Feb 2;24(3):2859. doi: 10.3390/ijms24032859.
5
Lung Inflammation in alpha-1-antitrypsin deficient individuals with normal lung function.α1-抗胰蛋白酶缺乏个体的肺部炎症，肺功能正常。
Respir Res. 2023 Feb 2;24(1):40. doi: 10.1186/s12931-023-02343-3.
6
Challenges Faced by Rural Primary Care Providers When Caring for COPD Patients in the Western United States.美国西部农村初级医疗服务提供者在照顾慢性阻塞性肺疾病（COPD）患者时面临的挑战。
Chronic Obstr Pulm Dis. 2021 Jul 28;8(3):336-349. doi: 10.15326/jcopdf.2021.0215.
本文引用的文献
1
Alpha-1-Antitrypsin Deficiency Liver Disease.α1-抗胰蛋白酶缺乏症肝病。
Clin Liver Dis. 2018 Nov;22(4):643-655. doi: 10.1016/j.cld.2018.06.010. Epub 2018 Aug 22.
2
Pharmacological Therapy of COPD: Reasons for Optimism.COPD 的药物治疗：乐观的理由。
Chest. 2018 Dec;154(6):1404-1415. doi: 10.1016/j.chest.2018.07.005. Epub 2018 Jul 17.
3
Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病的漏诊和过度诊断。
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1130-1139. doi: 10.1164/rccm.201804-0621CI.
4
Lessons from the Past: Some Histories of Alpha-1 Antitrypsin Deficiency Before Its Discovery.往昔之鉴：α-1抗胰蛋白酶缺乏症发现之前的一些历史
COPD. 2018 Feb;15(1):1-3. doi: 10.1080/15412555.2017.1421151.
5
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.α1抗胰蛋白酶用于治疗α1抗胰蛋白酶缺乏症相关肺部疾病：最新进展及临床意义
Int J Chron Obstruct Pulmon Dis. 2018 Jan 31;13:419-432. doi: 10.2147/COPD.S149429. eCollection 2018.
6
European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α-antitrypsin deficiency.欧洲呼吸学会声明：α-1 抗胰蛋白酶缺乏症相关肺部疾病的诊断与治疗。
Eur Respir J. 2017 Nov 30;50(5). doi: 10.1183/13993003.00610-2017. Print 2017 Nov.
7
The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.初级保健提供者在α-1抗胰蛋白酶缺乏症检测中的重要作用。
Postgrad Med. 2017 Nov;129(8):889-895. doi: 10.1080/00325481.2017.1381539. Epub 2017 Oct 5.
8
The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.成人α-1抗胰蛋白酶缺乏症的诊断与管理
Chronic Obstr Pulm Dis. 2016 Jun 6;3(3):668-682. doi: 10.15326/jcopdf.3.3.2015.0182.
9
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.全球、地区和国家慢性阻塞性肺疾病和哮喘的死亡、患病率、残疾调整生命年以及与残疾相关的生命年，1990-2015 年：2015 年全球疾病负担研究的系统分析。
Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16.
10
Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.α-1蛋白酶抑制剂在成年重症α-1抗胰蛋白酶缺乏症患者管理中的临床应用：当前文献综述
Drug Des Devel Ther. 2017 Jul 14;11:2149-2162. doi: 10.2147/DDDT.S105207. eCollection 2017.
Zotero 插件